8-K: Shattuck Labs Closes $103M Private Placement, Reshapes Board

Shattuck Labs, Inc. announced the closing of a private placement of up to $103 million and significant changes to its Board of Directors, including new appointments and resignations.

Summary

• Closed a private placement of up to approximately $103 million, led by OrbiMed, as previously disclosed.
• Proceeds from the financing, assuming full exercise of common stock warrants, are expected to fund operations into 2029.
• Funds will advance SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease.
• Four directors, Tyler Brous, Dr. Carrie Brownstein, Michael Lee, and Dr. Kate Sasser, resigned from the Board of Directors and any respective committees.
• The Board subsequently decreased its size from nine to seven directors.
• Dr. Daniel Baker and Dr. Mona Ashiya were appointed as new Class I directors, effective August 25, 2025.
• Dr. Baker was also appointed to the Board's Audit and Nominating and Corporate Governance Committees.
• OrbiMed, as a significant investor, is entitled to designate directors to the Board based on its ownership stake, with Dr. Ashiya serving as an OrbiMed Designee and Dr. Baker as an Independent Director Designee.
• SL-325 is described as a potential first-in-class Death Receptor 3 (DR3) blocking antibody.
• A Phase 1 clinical trial for SL-325 in healthy volunteers is expected to commence in the third quarter of 2025.

Sentiment

Score: 8

Explanation: The filing details a successful capital raise, a strategic refocusing of the company, and the addition of highly experienced individuals to the board, all of which are strong positive indicators for future development and financial stability. The only minor negative is the contingent nature of the full capital raise amount on warrant exercise.

Positives

• Successfully closed a private placement raising up to $103 million, providing substantial capital.
• Expected funding of operations into 2029, assuming full warrant exercise, indicating a strong financial runway.
• Strategic repositioning as an immunology and inflammation-focused organization, targeting a high-growth therapeutic area.
• Advancement of the lead program, SL-325, through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease.
• Appointment of Dr. Daniel Baker, an industry expert with over 20 years of drug development experience (including Remicade, Simponi, Stelara), to the Board and key committees.
• Appointment of Dr. Mona Ashiya, a Member at OrbiMed, strengthening investor representation and expertise on the Board.
• SL-325 is positioned as a potential first-in-class DR3 blocking antibody with superior efficacy and reduced immunogenicity potential compared to TL1A-blocking antibodies.
• Recent IND clearance for SL-325 enables progression to clinical trials.

Negatives

• Four directors resigned from the Board, representing a significant change in board composition, although stated not to be due to disagreements.
• The full $103 million from the private placement is contingent on the exercise of common stock warrants, which is not guaranteed.

Risks

• Global macroeconomic conditions and related volatility could impact operations and financial performance.
• Expected results of preclinical studies, clinical trials, and research and development programs may not materialize as anticipated.
• The unpredictable relationship between preclinical study results and clinical study results poses development risks.
• The timing or likelihood of regulatory filings and approvals for SL-325 is uncertain.
• Liquidity and capital resources may not be sufficient or could be impacted by unforeseen events, despite the recent financing.
• Actual results could materially differ from forward-looking statements due to various factors and uncertainties.
• The full $103 million from the private placement is contingent on the exercise of common stock warrants, which may not occur, affecting the total capital raised.

Future Outlook

Shattuck Labs expects the proceeds from the private placement, assuming full exercise of common stock warrants, to fund operations into 2029. The company plans to advance its lead program, SL-325, through multiple placebo-controlled, randomized Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease. A Phase 1 clinical trial for SL-325 in healthy volunteers is expected to commence in the third quarter of 2025, with multiple data readouts anticipated.

Management Comments

• "Our recent clearance for the SL-325 IND, closing of the private placement, and Board additions mark an important repositioning of Shattuck as an immunology and inflammation focused organization." Dr. Taylor Schreiber, CEO.
• "We believe SL-325 is a potentially first-in-class DR3 blocking antibody with the potential for superior efficacy and reduced immunogenicity relative to TL1A-blocking antibodies." Dr. Taylor Schreiber, CEO.
• "I look forward to leveraging my immunology and drug development background to help advance a novel DR3 blocking antibody as part of Shattuck’s Board of Directors and working with management to execute on its exciting development program in inflammatory bowel disease." Dr. Daniel Baker.
• "With SL-325 entering a Phase 1 trial this quarter, I am excited about the multiple data read outs ahead and the opportunity to help guide the program towards proof-of-concept studies." Dr. Daniel Baker.
• "I am pleased to be joining the Shattuck Board of Directors and share the Company’s strong commitment to improving outcomes for patients with immune-mediated diseases." Dr. Mona Ashiya.

Industry Context

This announcement reflects a strategic pivot for Shattuck Labs, focusing its resources on immunology and inflammation, a highly competitive but lucrative area within biotechnology. The emphasis on a 'first-in-class DR3 blocking antibody' for IBD positions the company against existing and emerging therapies, including TL1A-blocking antibodies, which are a current focus in the autoimmune space. The involvement of OrbiMed, a prominent healthcare investment firm, and the appointment of industry veterans like Dr. Baker, signal confidence in this strategic direction and the potential of SL-325.

Comparison to Industry Standards

• Dr. Daniel Baker's experience includes contributing to the development of Remicade, Simponi, and Stelara at Johnson & Johnson, which are established, blockbuster immunology drugs, setting a high bar for the potential impact of SL-325.
• SL-325 is positioned as potentially superior to TL1A-blocking antibodies, a current area of significant industry interest for inflammatory diseases, suggesting Shattuck aims to differentiate its approach in a competitive landscape.
• Dr. Mona Ashiya serves on the board of Disc Medicine, Inc. (NASDAQ: IRON), a company focused on treating serious hematologic diseases, indicating her experience with innovative biotech companies.

Management Changes

Corporate Governance

Related Party Transactions

• Dr. Mona Ashiya is a Member at OrbiMed Advisors LLC, which led the private placement and has director designation rights. She is serving as an OrbiMed Designee on the Board.
• Dr. Daniel Baker was appointed as an Independent Director Designee pursuant to a letter agreement with OrbiMed, entered into in connection with the Securities Purchase Agreement.

Stakeholder Impact

• Shareholders: Potential for increased share price due to significant capital raise, extended cash runway, strategic focus, and strengthened board. Potential for dilution from the private placement and future warrant exercise.
• Employees: Strategic refocusing on immunology and inflammation may lead to clearer R&D priorities and potentially enhanced job security due to extended funding.
• Customers/Patients: Accelerated development of SL-325 could lead to new treatment options for inflammatory and immune-mediated diseases.
• Creditors: Improved financial stability and extended cash runway reduce short-term credit risk.

Next Steps

• Commence a Phase 1 clinical trial for SL-325 in healthy volunteers in Q3 2025.
• Advance SL-325 through multiple placebo-controlled, randomized Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease.
• Dr. Baker and Dr. Ashiya intend to enter into the Company's standard form of indemnification agreement.

Key Dates

Recommendation

The successful closing of a substantial private placement, led by a reputable institutional investor like OrbiMed, significantly de-risks Shattuck Labs' financial position, extending its cash runway into 2029. The strategic pivot to focus on immunology and inflammation, particularly with the promising SL-325 program, aligns the company with a high-growth therapeutic area. The addition of Dr. Daniel Baker, an industry veteran with a track record in developing blockbuster immunology drugs, and Dr. Mona Ashiya from OrbiMed, substantially strengthens the Board's expertise and oversight. These factors collectively provide a strong positive outlook for the company's future development and potential for value creation.

Keywords

Shattuck Labs, STTK, Private Placement, Board of Directors, Biotechnology, Immunology, Inflammation, SL-325, DR3 blocking antibody, Inflammatory Bowel Disease, OrbiMed, Clinical Trials, Drug Development, Corporate Governance